Abiopharma

🔍 FOSTER VINCENT D (Executive)

Company: Main Street Capital CORP (MAIN)

Report Date: 2026-05-04

Detailed Transactions and Holdings:

• Acquired 13 shares of Common Stock at $56.39 per share (Direct)
  Date: 2026-04-15 | Code: J | equity_swap_involved: 0 | shares_owned_after: 1,740,372.26 | transaction_form_type: 5 | Footnotes: F1
• Acquired 1,385 shares of Common Stock at $56.39 per share (Direct)
  Date: 2026-04-15 | Code: J | equity_swap_involved: 0 | shares_owned_after: 1,741,757.08 | transaction_form_type: 5 | Footnotes: F1
• Acquired 538 shares of Common Stock (Direct)
  Date: 2026-05-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,742,295.08 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-04 | Code: H | nature_of_ownership: MS Trust I | shares_owned_after: 35,307.47 | Footnotes: F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-04 | Code: H | nature_of_ownership: MS Trust II | shares_owned_after: 34,557.00 | Footnotes: F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-04 | Code: H | nature_of_ownership: MS Trust III | shares_owned_after: 34,557.00 | Footnotes: F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-04 | Code: H | nature_of_ownership: MS Trust V | shares_owned_after: 33,300.00 | Footnotes: F3

Footnotes:

• F1: The reporting person acquired these shares under a dividend reinvestment plan, pursuant to a dividend reinvestment transaction exempt from Section 16 under Rule 16a-11.
• F2: Shares issued under the Main Street Capital Corporation Non-Employee Director Restricted Stock Plan.
• F3: Family trust